PMID- 29350109
OWN - NLM
STAT- MEDLINE
DCOM- 20181221
LR  - 20190301
IS  - 1557-9077 (Electronic)
IS  - 1050-7256 (Print)
IS  - 1050-7256 (Linking)
VI  - 28
IP  - 3
DP  - 2018 Mar
TI  - Tertiary Care Experience of Sorafenib in the Treatment of Progressive 
      Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter 
      Study.
PG  - 340-348
LID - 10.1089/thy.2017.0356 [doi]
AB  - BACKGROUND: Sorafenib, a multi-kinase inhibitor, is approved for the treatment of 
      patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer 
      (DTC). This study evaluated the efficacy and safety of sorafenib in real-world 
      clinical practice and compared the results to those of the DECISION trial. The 
      clinical features associated with better clinical outcomes after sorafenib 
      treatment were also evaluated. METHODS: This multicenter, retrospective cohort 
      study evaluated 98 patients with progressive RAI-refractory DTC who were treated 
      with sorafenib in six tertiary hospitals in Korea. The primary objective was the 
      progression-free survival (PFS) according to Response Evaluation Criteria In 
      Solid Tumors v1.1. Overall survival, response rate (defined as the best objective 
      response according to Response Evaluation Criteria In Solid Tumors v1.1), and 
      safety were also evaluated. RESULTS: The median PFS was 9.7 months; median 
      overall survival was not reached during follow-up. Partial responses and stable 
      disease were achieved in 25 (25%) and 64 (65%) patients, respectively. Stable 
      disease of >6 months was achieved in 41 (42%) patients. Subgroup analyses 
      identified several prognostic indicators of a better PFS: absence of 
      disease-related symptoms (hazard ratio [HR] = 0.5; p = 0.041), lung-only 
      metastasis (HR = 0.4; p = 0.048), a daily maintenance dose >/=600 mg (HR = 0.3; 
      p = 0.005), and a thyroglobulin reduction >/=60% (HR = 0.4; p = 0.012). The mean 
      daily dose of sorafenib was 666 +/- 114 mg, and drug withdrawals due to adverse 
      events (AEs) occurred in 13% of patients. AEs and serious AEs were reported in 93 
      (95%) and 40 (41%) patients, respectively. The most frequent AE was hand-foot 
      skin reaction (76%). CONCLUSIONS: The PFS of progressive RAI-refractory DTC 
      patients treated with sorafenib was consistent with the findings of the DECISION 
      trial. Disease-related symptoms, lung-only metastasis, a daily maintenance dose, 
      and thyroglobulin reduction were significantly associated with PFS. These results 
      suggest that sorafenib is an effective treatment option for patients with 
      progressive RAI-refractory DTC.
FAU - Kim, Mijin
AU  - Kim M
AD  - 1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan 
      Medical Center, University of Ulsan College of Medicine , Seoul, Korea.
FAU - Kim, Tae Hyuk
AU  - Kim TH
AD  - 2 Division of Endocrinology and Metabolism, Department of Medicine, Thyroid 
      Center, Samsung Medical Center, Sungkyunkwan University School of Medicine , 
      Seoul, Korea.
FAU - Shin, Dong Yeob
AU  - Shin DY
AD  - 3 Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Severance Hospital, Yonsei University College of Medicine , Seoul, Korea.
FAU - Lim, Dong Jun
AU  - Lim DJ
AD  - 4 Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Seoul St. Mary's Hospital, The Catholic University of Korea , Seoul, Korea.
FAU - Kim, Eui Young
AU  - Kim EY
AD  - 5 Department of Endocrinology, Dongnam Institute of Radiological and Medical 
      Sciences Cancer Center , Busan, Korea.
FAU - Kim, Won Bae
AU  - Kim WB
AD  - 1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan 
      Medical Center, University of Ulsan College of Medicine , Seoul, Korea.
FAU - Chung, Jae Hoon
AU  - Chung JH
AD  - 2 Division of Endocrinology and Metabolism, Department of Medicine, Thyroid 
      Center, Samsung Medical Center, Sungkyunkwan University School of Medicine , 
      Seoul, Korea.
FAU - Shong, Young Kee
AU  - Shong YK
AD  - 1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan 
      Medical Center, University of Ulsan College of Medicine , Seoul, Korea.
FAU - Kim, Bo Hyun
AU  - Kim BH
AD  - 6 Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Biomedical Research Institute, Pusan National University Hospital , Busan, Korea.
FAU - Kim, Won Gu
AU  - Kim WG
AD  - 1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan 
      Medical Center, University of Ulsan College of Medicine , Seoul, Korea.
CN  - Korean Thyroid Cancer Study Group (KTCSG)
LA  - eng
PT  - Journal Article
DEP - 20180216
PL  - United States
TA  - Thyroid
JT  - Thyroid : official journal of the American Thyroid Association
JID - 9104317
RN  - 0 (Antineoplastic Agents)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
EIN - Thyroid. 2018 May;28(5):686. PMID: 29749906
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Progression-Free Survival
MH  - Republic of Korea
MH  - Retrospective Studies
MH  - Sorafenib/*therapeutic use
MH  - Survival Analysis
MH  - Survival Rate
MH  - Tertiary Healthcare
MH  - Thyroid Neoplasms/*drug therapy/mortality/pathology
MH  - Treatment Outcome
PMC - PMC6225595
OTO - NOTNLM
OT  - progression-free survival
OT  - radioactive iodine refractory
OT  - real-world clinical practice
OT  - sorafenib
OT  - thyroid neoplasm
COIS- The authors have nothing to disclose.
FIR - Kim, Mijin
IR  - Kim M
FIR - Jeon, Minji
IR  - Jeon M
FIR - Kim, Won Gu
IR  - Kim WG
FIR - Kim, Tae Yong
IR  - Kim TY
FIR - Kim, Won Bae
IR  - Kim WB
FIR - Shong, Young Kee
IR  - Shong YK
FIR - Kim, Tae Hyuk
IR  - Kim TH
FIR - Kim, Sun Wook
IR  - Kim SW
FIR - Chung, Jae Hoon
IR  - Chung JH
FIR - Shin, Dong Yeob
IR  - Shin DY
FIR - Jo, Young Suk
IR  - Jo YS
FIR - Lee, Eun-Jig
IR  - Lee EJ
FIR - Lim, Dong Jun
IR  - Lim DJ
FIR - Kim, Min-Hee
IR  - Kim MH
FIR - Kang, Moo Il
IR  - Kang MI
FIR - Kim, Eui Young
IR  - Kim EY
FIR - Jang, Eun Kyung
IR  - Jang EK
FIR - Kim, Bo Hyun
IR  - Kim BH
FIR - Kim, In Joo
IR  - Kim IJ
EDAT- 2018/01/20 06:00
MHDA- 2018/12/24 06:00
PMCR- 2019/03/01
CRDT- 2018/01/20 06:00
PHST- 2018/01/20 06:00 [pubmed]
PHST- 2018/12/24 06:00 [medline]
PHST- 2018/01/20 06:00 [entrez]
PHST- 2019/03/01 00:00 [pmc-release]
AID - 10.1089/thy.2017.0356 [pii]
AID - 10.1089/thy.2017.0356 [doi]
PST - ppublish
SO  - Thyroid. 2018 Mar;28(3):340-348. doi: 10.1089/thy.2017.0356. Epub 2018 Feb 16.